 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
6-13-2025
Insider Buy |
Patrick J. Heron
|
$13.08
CAGR »
|
$34,610.47
2,646 shares |
6-5-2025
Insider Buy |
Patrick J. Heron
|
$13.34
CAGR »
|
$30,246.73
2,268 shares |
5-22-2025
Insider Buy |
Patrick J. Heron
|
$13.65
CAGR »
|
$68,821.20
5,040 shares |
5-15-2025
Insider Buy |
Patrick J. Heron
|
$13.62
CAGR »
|
$34,316.86
2,520 shares |
5-14-2025
Insider Buy |
Patrick J. Heron
|
$13.76
CAGR »
|
$119,351.93
8,674 shares |
5-9-2025
Insider Buy |
Patrick J. Heron
|
$13.60
CAGR »
|
$85,691.34
6,300 shares |
11-30-2024
Insider Buy |
Larry Todd Edwards
See Remarks |
$7.11
CAGR »
|
$7,766.86
1,093 shares |
11-30-2024
Insider Buy |
Masaru Matsuda
See Remarks |
$3.28
CAGR »
|
$18,542.64
5,657 shares |
11-30-2024
Insider Buy |
Todd Franklin Watanabe
See Remarks |
$3.52
CAGR »
|
$21,250.03
6,038 shares |
3-4-2024
Insider Buy |
Patrick J. Heron
|
$9.50
CAGR »
|
$199,994.00
21,052 shares |
12-1-2023
Insider Buy |
Todd Franklin Watanabe
See Remarks |
$6.38
CAGR »
|
$9,333.94
1,463 shares |
10-24-2023
Insider Buy |
Frazier Life Sciences VIII, L.P.
>10% Owner |
$2.50
CAGR »
|
$200,000.00
80,000 shares |
8-5-2022
Insider Buy |
Frazier Life Sciences VIII, L.P.
>10% Owner |
$20.00
CAGR »
|
$5,000,000.00
250,000 shares |
10-2-2020
Insider Buy |
Jonathan Silverstein
Director and >10% Owner |
$25.00
CAGR »
|
$12,400,000.00
496,000 shares |
10-2-2020
Insider Buy |
ORBIMED ADVISORS LLC
Director and >10% Owner |
$25.00
CAGR »
|
$12,400,000.00
496,000 shares |
2-4-2020
Insider Buy |
Bain Capital Life Sciences Investors, LLC
>10% Owner |
$17.00
CAGR »
|
$4,999,989.00
294,117 shares |
2-4-2020
Insider Buy |
ORBIMED ADVISORS LLC
Director and >10% Owner |
$17.00
CAGR »
|
$9,501,096.00
558,888 shares |
2-4-2020
Insider Buy |
Jonathan Silverstein
Director and >10% Owner |
$17.00
CAGR »
|
$9,501,096.00
558,888 shares |
2-4-2020
Insider Buy |
Patrick J. Heron
Director and >10% Owner |
$17.00
CAGR »
|
$8,500,000.00
500,000 shares |
2-4-2020
Insider Buy |
Frazier Life Sciences VIII, L.P.
>10% Owner |
$17.00
CAGR »
|
$8,500,000.00
500,000 shares |
Also See: Institutional Holders of ARQT
Also See: SEC filings
Below we present the annualized performance delivered by ARQT stock since 6-13-2025 (the date of the most recent
insider purchase). The performance of the investment from the time ARQT insider buying occurred is the ultimate
test of whether insiders were right about ARQT being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/16/2025 |
|
| End date: |
01/14/2026 |
|
| Start price/share: |
$13.40 |
|
| End price/share: |
$26.73 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
99.48% |
|
| Annualized Gain: |
171.27% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$19,948.00 |
|
| Years: |
0.58 |
|
ARQT Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent ARQT insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding ARQT
|
|
Free ARQT Email Alerts:
